<H2>
Legislation aims to expand National Asthma Control Program to all 50 states
</H2> |
<H2>
Partnership to develop gene editing therapies for neurological, muscular diseases
</H2> |
<H2>
Boehringer Ingelheim Humira biosimilar available at low wholesale acquisition cost
</H2> |
<H2>
Takeda plans voluntary withdrawal of Exkivity approval for non-small cell lung cancer
</H2> |
<H2>
Revumenib trial meets complete remission endpoint for acute leukemia subsets
</H2> |
<H2>
FDA issues complete response letter for relabotulinumtoxinA for frown lines, crow’s feet
</H2> |
<H2>
Use of AI software led to improved outcomes for those with intracranial hemorrhage
</H2> |
<H2>
Precision navigators reduce racial disparities in genomic testing for prostate cancer
</H2> |
<H2>
Top in endocrinology: Tirzepatide outperforms semaglutide; FDA rejects GLP-1 implant
</H2> |
<H2>
BLOG: My evolving approach to mix and match
</H2> |
<H2>
Retina360: Advances in the Management of nAMD
</H2> |
<H2>
COVID-19 in Immunocompromised Patients: Is Prevention Better Than Cure? – A Podcast Series
</H2> |
<H2>
Oncology Innovations: LAG3 Inhibition in Melanoma Treatment
</H2> |
<H2>
Ace the Case: A 32-Year-Old Woman With Diarrhea
</H2> |
<H2>
Ace the Case: A 54-Year-Old Woman With Hot Flashes
</H2> |
<H2>
Ace the Case: A 70-Year-Old Woman With Weight Loss and New-Onset Headaches
</H2> |
<H2>
Medical Crossfire®: Expert Insights in Anti-VEGF Dosing for nAMD and DME – Optimizing Reduction in Treatment Burden
</H2> |
<H2>
Ace the Case: A 46-Year-Old Woman With Non-Type 2 Asthma
</H2> |
<H2> Update email address </H2> |
<H2> We’re sorry, but an unexpected error has occurred. </H2> |
<H3>
News
</H3> |
<H3> CME </H3> |
<H3>
Clinical Guidance
</H3> |
<H3> Ankylosing Spondylitis </H3> |
<H3> Atopic Dermatitis </H3> |
<H3> Genomics </H3> |
<H3> Immuno-Oncology </H3> |
<H3> Lipid Management </H3> |
<H3> Obesity </H3> |
<H3> Psoriasis </H3> |
<H3> Psoriatic Arthritis </H3> |
<H3> Type 2 Diabetes </H3> |
<H3> Ulcerative Colitis </H3> |
<H5> Play on Healio </H5> |
<H5> Follow Healio </H5> |
<H5> About </H5> |
<H5> Account Information </H5> |
<H5> Contact Us </H5> |
<H5> Legal </H5> |
<H5> Sign Up for Email </H5> |
Social
Social Data
Cost and overhead previously rendered this semi-public form of communication unfeasible.
But advances in social networking technology from 2004-2010 has made broader concepts of sharing possible.